Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ryanair Holdings plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.45 (market cap $505.73M), while Ryanair Holdings plc trades at $59.41 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 58.6× Ginkgo Bioworks Holdings Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | RYAAY | |
|---|---|---|
Market Cap | $505.73M | $29.63B |
Sector | Health | Industrials |
52-Week High | $16.14 | $73.82 |
52-Week Low | $5.48 | $53.24 |
Enterprise Value | $607.68M | $26.61B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Ryanair Holdings (RYAAY) trades at $59.41, down 0.17% with bearish technical signals despite reasonable valuations (P/E 14.37). The airline reported mixed quarterly results with Q1 2026 beating expectations but Q2 2026 missing, while maintaining strong profitability (22.41% ROE) and a solid balance sheet with $3.96B cash. Recent news highlights operational challenges from lower fares and fuel costs, alongside strategic AI partnerships.
Outlook remains cautious due to near-term headwinds from fare pressure and geopolitical risks, but long-term prospects are supported by industry consolidation potential and strong financials. Analyst consensus is bullish (62.5% Buy ratings), viewing current weakness as overdone. Key risks include fuel price volatility and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
